Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)

Biologics targeting TNF have brought about a paradigm shift in the treatment of rheumatoid arthritis (RA) and infliximab, anti-TNF-α chimeric monoclonal antibody, was marketed in 2003 in Japan. We previously reported on the RECONFIRM study, a retrospective clinical study on the efficacy of inflixima...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yoshiya, Takeuchi, Tsutomu, Inoue, Eisuke, Saito, Kazuyoshi, Sekiguchi, Naoya, Sato, Eri, Nawata, Masao, Kameda, Hideto, Iwata, Shigeru, Amano, Kouichi, Yamanaka, Hisashi
Formato: Texto
Lenguaje:English
Publicado: Springer Japan 2008
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2279153/
https://www.ncbi.nlm.nih.gov/pubmed/18283523
http://dx.doi.org/10.1007/s10165-008-0026-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2279153/
https://www.ncbi.nlm.nih.gov/pubmed/18283523
http://dx.doi.org/10.1007/s10165-008-0026-3

Ejemplares similares